Mankind Pharma export revenue rises 33% as mix broadens
Key highlights
- Mankind Pharma’s international revenue rose 33% year-on-year to Rs 680 crore in Q2 FY27.
- Other international markets grew 37% in Q2 FY27, ahead of 29% growth in the US business.
- BSV revenue increased 34% in Q2 FY27, supported by specialty products in fertility, critical care and women’s health.
- Mankind Pharma retained FY27 EBITDA margin guidance of 25.5% to 26.5% and 20% constant-currency dollar export-growth guidance.
powered by IRIS

Mankind Pharma Limited reported international revenue of Rs 680 crore in Q2 FY27, up 33% year-on-year and faster than its 17.3% consolidated revenue growth. Management said BSV branded specialty products, new US launches and other international markets drove the result, with non-US branded markets now contributing almost as much as the US.
Know Mankind Pharma inside out
Results, valuation, peers and who's buying, in one view.
How fast did Mankind Pharma’s international business grow?
Mankind Pharma’s international revenue grew 33% year-on-year to Rs 680 crore in Q2 FY27. The increase exceeded management’s 20% export-growth guidance on a constant-currency dollar basis, although management said currency exchange benefit accounted for the gap between that underlying benchmark and actual growth above 30%.
Chief Financial Officer Ashutosh Dhawan said the export guidance was set at 20% growth on a constant-currency dollar basis. He said actual growth was upward of 30%, with currency movements contributing to the difference, so the 33% reported revenue increase should not be read as a like-for-like constant-currency rate.
International revenue represented a faster-growing part of Mankind Pharma’s Q2 FY27 business, while the domestic business remained much larger at Rs 3,657 crore. The transcript did not disclose Q2 FY26 international revenue or a country-level revenue split, limiting a calculation of export-market shares from reported figures.
What is driving Mankind Pharma’s export growth?
Mankind Pharma said growth came from both its own international operations and BSV’s branded specialty business. Management identified BSV specialty products and new US launches as operating drivers, in addition to the currency benefit described for the reported export-growth rate.
BSV grew 34% in Q2 FY27, while Mankind Pharma’s US business grew 29% and its other international markets grew 37%. The 37% expansion outside the US was the fastest among the three disclosed growth rates, while BSV’s growth showed continued momentum in the specialty portfolio.
BSV is expanding global adoption of products in fertility, critical care and women’s health, according to management. The company said its BSV portfolio delivered growth above 20% for a second consecutive quarter across domestic and international markets, though it did not disclose separate overseas revenue or profitability for BSV.
Mankind Pharma also cited new US product launches alongside branded specialty growth. The call did not identify the launches or provide their revenue contribution, so the relative weight of new US products, BSV products and other markets within the Rs 680 crore international revenue total was not disclosed.
Is Mankind Pharma becoming less dependent on the US?
Yes. Mankind Pharma management said the US market and other branded markets are now “almost more or less equal” in their contribution to exports. Management also said it expects emerging markets to overtake the US in export contribution, without giving a date or a revenue target for that change.
This marks a shift from the export mix described by an analyst on the Q2 FY27 call, who said the US had represented about 70% to 75% of the overall export market one to two years earlier. Management did not challenge that historical characterisation and instead said other branded markets and the US are now near parity.
The current-quarter growth rates support the direction of the mix change: other international markets grew 37%, compared with 29% in the US. However, Mankind Pharma did not provide absolute revenue by geography, so the size of either market or the exact distance between their contributions cannot be quantified from the call.
Management’s expectation that emerging markets will take over from the US remains forward-looking. It is tied to the expansion of differentiated products, including BSV’s fertility, critical-care and women’s-health portfolio, rather than to a disclosed country-by-country rollout plan.
Got a follow-up? Ask IRIS
How does international growth compare with domestic growth?
Mankind Pharma’s 33% international growth in Q2 FY27 was more than twice the 14.8% increase in domestic-business revenue. Domestic revenue was Rs 3,657 crore, compared with Rs 680 crore internationally, showing that India remained the group’s substantially larger revenue base despite faster overseas growth.
The domestic result was driven by 16% growth in Mankind Pharma’s core domestic business excluding consumer healthcare and mid-teen growth in BSV’s domestic business. Consumer healthcare was softer because of slower category offtake and regional effects in East and South India, according to management.
Mankind Pharma also reported 23% year-on-year hospital-revenue growth during Q2 FY27. Management linked domestic hospital expansion to specialist engagement and targeted launches, whereas its international strategy is centred on branded specialty products, new US launches and a broader geographic mix.
At the consolidated level, revenue from operations rose 17.3% to Rs 4,338 crore in Q2 FY27 from Rs 3,697 crore a year earlier. Earnings before interest, tax, depreciation and amortisation margin increased to 27.1% from 25.0%, with management attributing the 210-basis-point improvement to gross-margin expansion, lower research and development expense and operating leverage.
What is Mankind Pharma expecting next?
Mankind Pharma management said it expects double-digit growth in its international business in FY27. The company retained its 20% constant-currency dollar export-growth guidance, which remains the stated underlying benchmark after Q2 FY27’s reported result benefited from currency exchange movements.
Management retained group earnings before interest, tax, depreciation and amortisation margin guidance of 25.5% to 26.5% for FY27. It also said research and development expense should be near the upper end of its 2.8% to 3.0% revenue guidance, including the effect of Armed Cell Therapeutics.
The company had net debt of Rs 2,639 crore as of September 30, 2026, equal to 0.6 times adjusted earnings before interest, tax, depreciation and amortisation on a trailing-12-month basis. Management said it remains on track to repay acquisition-related debt by FY28, while its current commitment to Armed Cell Therapeutics totals EUR 48 million and is expected to cover funding through FY28.
Conclusion
Mankind Pharma’s Q2 FY27 result showed that international growth is no longer dependent solely on the US: overseas revenue rose 33% to Rs 680 crore, BSV grew 34%, and other international markets grew 37% against 29% in the US. Management said non-US branded markets and the US are now almost equal contributors, a substantial change from the earlier US-heavy mix discussed on the call.
Next, the key disclosed measures are whether Mankind Pharma delivers its FY27 constant-currency export-growth guidance of 20%, sustains double-digit international growth and sees emerging markets exceed the US contribution as management expects. The company’s FY27 margin range of 25.5% to 26.5% and research and development spending near 3% of revenue will also frame how group expansion translates into operating results.


